Manufacturer record
Pharmaroots Healthcare: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
15 batches manufactured by Pharmaroots Healthcare (Himachal Pradesh) were declared Not of Standard Quality between September 2023 and July 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
15 records linked to Pharmaroots Healthcare in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Clopidogrel & Aspirin Tablets IP | P0825176TMfg 2025-08 · Exp 2027-07 | Dissolution, Free Salicylic Acid, Content of Clopidogrel (38.20%) and Aspirin (21.8%)Dissolution | Drugs Testing Laboratory, Chennai-06State lab | Jul 2026 |
| Ramipril Tablets IP 2.5 MG | PT-51725Mfg 2025-05 · Exp 2027-04 | The sample does not conform to claim as per IP 2022 in respect to the test of Dissolution and Assay of RamiprilAssay | RDTL, ChandigarhCDSCO lab | Mar 2026 |
| Aluminium Hydroxide, Magnesium Hydroxide & Simethicone Oral Suspension IP | PL-40143Mfg 2024-06 · Exp 2026-05 | Content and Microbial LimitMicrobial limits | Drugs Testing Laboratory, Chennai-06State lab | Jan 2026 |
| Telmisartan Tablets IP 40mg Savtel 40 Tablets | PT- 40584Mfg 2024-02 · Exp 2026-01 | The sample does not comply as per I.P. 2022 with respect to The test for Dissolution of Telmisartan.Dissolution | RDTL, GuwahatiCDSCO lab | Dec 2025 |
| Ramipril Tablets IP 2.5 mg | PT-44206Mfg 2024-12 · Exp 2026-11 | Test for Dissolution & Assay for RAmiprilAssay | RDTL, Hubli, KarnatakaState lab | Nov 2025 |
| Savtel Telmisartan Tablets IP 40 mg. | PT-40585Mfg 2024-02 · Exp 2026-01 | sample does not conform to claim as per I.P. 2022 in respect to the Test of DissolutionDissolution | RDTL, GuwahatiCDSCO lab | Sep 2025 |
| Telmisartan Tablets IP 40mg (Savtel 40 Tablets) | PT-40586Mfg 2024-02 · Exp 2026-01 | Dissolution of TelmisartanDissolution | RDTL, GuwahatiCDSCO lab | Jul 2025 |
| Telmisartan Tablets IP 40mg (Savtel 40 Tablets) | PT-40584Mfg 2024-02 · Exp 2026-01 | DissolutionDissolution | RDTL GuwahatiCDSCO lab | Feb 2025 |
| Isosorbide Dinitrate Tablets IP [ISOMIC 10] | PT- 42968Mfg 2024-08 · Exp 2026-07 | The sample does not conform to identification test for Isosorbide Dinitrate as per IP. Hence the sample is spurious and declared as Not of Standard QualityIdentification | DTL ThiruvananthapuramState lab | Feb 2025 |
| CALCIUM CARBONATE TABLETS IP 500 mg. | PT-30670Mfg 2023-04 · Exp 2025-03 | DisintegrationDisintegration | RDTL GuwahatiState lab | Mar 2024 |
| CALCIUM CARBONATE TABLETS IP 500 mg. | PT-30665Mfg 2023-04 · Exp 2025-03 | MisbrandedMisbranded | RDTL GuwahatiState lab | Mar 2024 |
| TESCALVIT D3 Tablets (Calcium Carbonate & Vitamin D3 Tablets) | PT-30296Mfg 2023-02 · Exp 2025-01 | Assay of Vitamin D3 and DescriptionAssay | CDL KolkataCDSCO lab | Dec 2023 |
| Glimepiride Tablets IP.. (Glimnol-1 Tablets) | PT-22953Mfg 2023-01 · Exp 2024-12 | DissolutionDissolution | RDTL GuwahatiState lab | Dec 2023 |
| AMLODIPINE BESYLATE TABLETS I.P. 5 mg. (AMLOMART-5 mg TABLETS) | PT-31011Mfg 2023-04 · Exp 2025-03 | Assay of AmlodipineAssay | RDTL GuwahatiState lab | Oct 2023 |
| CALCIUM CARBONATE TABLETS IP 500 mg. | PT-30625Mfg 2023-04 · Exp 2025-03 | Disintergrati onOther | RDTL GuwahatiState lab | Sep 2023 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.